









Markets
/
Stocks
/
nasdaq-tara
/

Protara Therapeutics Inc

TARA

6.650USD

+0.150+2.31%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

256.61MMarket Cap

LossP/E TTM



Protara Therapeutics Inc

6.650

+0.150+2.31%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Protara Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Protara Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 55 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.50.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Protara Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

55 / 392

Overall Ranking

174 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Protara Therapeutics Inc Highlights

StrengthsRisks

Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.

Undervalued

The company’s latest PE is -4.78, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 27.23M shares, decreasing 24.71% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 314.30K shares of this stock.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

25.500

Target Price

+292.31%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Protara Therapeutics Inc is 7.14, ranking 150 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.14

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.93

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.04

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Protara Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Protara Therapeutics Inc is 7.05, ranking 182 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -4.78, which is -96.16% below the recent high of -0.18 and -13.69% above the recent low of -5.43.

Score

Industry at a Glance

Previous score

7.05

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 55/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Protara Therapeutics Inc is 8.29, ranking 137 out of 392 in the Biotechnology & Medical Research industry. The average price target is 25.00, with a high of 30.00 and a low of 21.00.

Score

Industry at a Glance

Previous score

8.29

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

25.500

Target Price

+292.31%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Protara Therapeutics Inc

TARA

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Protara Therapeutics Inc is 9.25, ranking 27 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 7.81 and the support level at 5.11, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.17

Change

0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.053

Buy

RSI(14)

58.062

Neutral

STOCH(KDJ)(9,3,3)

36.469

Sell

ATR(14)

0.512

Low Volatility

CCI(14)

20.221

Neutral

Williams %R

30.153

Buy

TRIX(12,20)

1.083

Sell

StochRSI(14)

20.273

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

6.730

Sell

MA10

6.884

Sell

MA20

6.160

Buy

MA50

5.967

Buy

MA100

5.473

Buy

MA200

4.338

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Protara Therapeutics Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 52.73%, representing a quarter-over-quarter decrease of 32.64%. The largest institutional shareholder is The Vanguard, holding a total of 2.39M shares, representing 4.63% of shares outstanding, with 11.51% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Janus Henderson Investors

4.23M

+3.14%

The Vanguard Group, Inc.

Star Investors

1.90M

+5.67%

Velan Capital Investment Management LP

2.14M

BlackRock Institutional Trust Company, N.A.

2.05M

+4.18%

Blackstone Alternative Asset Management, L.P.

1.91M

Acorn Capital Advisors, LLC

1.75M

Catalio Capital Management, LP

1.50M

-7.72%

Integral Health Asset Management, LLC

1.40M

UBS Financial Services, Inc.

843.07K

-25.66%

5AM Ventures

800.00K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Protara Therapeutics Inc is 3.34, ranking 149 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.40. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.